A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Posaconazole (Primary) ; Posaconazole (Primary) ; Voriconazole; Voriconazole
- Indications Invasive bronchopulmonary aspergillosis
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 30 Sep 2019 Status changed from active, no longer recruiting to completed.
- 16 Aug 2019 Planned End Date changed from 30 Sep 2019 to 18 Sep 2019.
- 19 Jun 2019 The trial has been completed in Czech Republic as per European Clinical Trials Database record.